Nov 21,2018

CDC recognizes Livongo's DPP

Digital chronic care company Livongo Health’s Diabetes Prevention Program has received full recognition from the CDC, according to a release from the company. The designation implies that the digital offering meets the agency’s standards as a Type 2 diabetes prevention and lifestyle change intervention, and is listed within the CDC’s online referral tool.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Nov 29,2018

Meet the five Startup Battlefield finalists at Disrupt Berlin 2018

Spike App and the other 4 digital health startups were chosen as finalists at Disrupt Berlin. These finalists will all take the stage again to present in front of a new set of judges, who will have time to ask more in-depth questions. Then one winner will be chosen to take home the Disrupt Cup — not to mention $50,000, equity-free.

View Analyst & Ambassador Comments
Go to original news
Nov 01,2018

Insulet Reports Third Quarter 2018 Revenue of $151.1 Million, Up 24% Year-Over-Year, and Gross Margin Over 67%, Up 700 Basis Points

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months ended September 30, 2018. Third quarter revenue of $151.1 million, was up by 24%, compared to revenue of $121.8 million in the prior year, and guidance of $144.5 to $151.5 million

View Analyst & Ambassador Comments
Go to original news
Nov 01,2018

Tandem Diabetes Care Reports Third Quarter 2018 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2018. Total pump shipments of 8,434 included 1,055 pumps for the launch of international operations to select geographies outside the United States, which commenced in August 2018. This resulted in international sales of $2.5 million, or 5 percent of total sales of $46.3 million in the third quarter of 2018.

View Analyst & Ambassador Comments
Go to original news
Nov 05,2018

Insulet Raises Awareness for National Diabetes Awareness Month

Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it is recognizing National Diabetes Awareness Month with initiatives that highlight Insulet’s continued commitment to raising awareness for diabetes. This year’s activities are focused on the theme “freedom”.

View Analyst & Ambassador Comments
Go to original news
Nov 06,2018

BD Announces Results For 2018 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2019 Guidance

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.402 billion for the fourth fiscal quarter ended September 30, 2018.

View Analyst & Ambassador Comments
Go to original news
Nov 06,2018

DarioHealth to Host Third Quarter 2018 Conference Call on November 13, 2018

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its third quarter 2018 results on Tuesday, November 13, and host a conference call the same morning at 9:00am EDT.

View Analyst & Ambassador Comments
Go to original news
Nov 06,2018

Senseonics Announces FDA Approval to Expand Eversense® CGM Certification to Nurse Practitioners and Physician Assistants

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that the Eversense® Continuous Glucose Monitoring (CGM) System has received FDA approval for qualified health care providers to be trained and certified to provide patients with the highly accurate sensor that lasts up to three months.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 07,2018

07 Nov, 2018 Brighter draws down the eighth tranche under the financing agreement with L1 Capital and issues additional free warrants to its shareholders.

Brighter has called upon a eighth Tranche of SEK 10 million in line with the terms from the financing agreement communicated on the 26thof April 2017. The transaction is carried out through a private placement of convertible notes with warrants attached. It is the eighth tranche out of a commitment totaling SEK 100 million.

View Analyst & Ambassador Comments
Go to original news
Nov 07,2018

Nemaura Successfully Develops Predictive Algorithms and Alarm Functionality for Continuous Glucose Monitor SugarBEAT®

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today announced the successful development of predictive algorithms that will allow the inclusion of alarms in its sugarBEAT® CGM. Results indicate the alarm functionality can predict glucose level 5 minutes in advance with 98% accuracy, 10 minutes in advance with 95% accuracy and 15 minutes in advance with 90% accuracy.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES